1. Phylogeny  
Interleukin‑1 receptor‑associated kinase 4 (IRAK4) is a member of the IRAK family of kinases, a group of serine/threonine protein kinases that share a common evolutionary origin and functional role in innate immune signaling. IRAK4 possesses a characteristic domain architecture composed of an N‑terminal death domain (DD) and a C‑terminal kinase domain, and its conservation has been demonstrated across vertebrate species. Orthologs of IRAK4 have been identified in a wide range of organisms, from mammals to more basal vertebrates, and even in some invertebrate species where proteins with similar domain organization such as Drosophila’s Pelle or Tube‑like kinases perform analogous functions. Comparative phylogenetic analyses reveal that IRAK4 represents, within the human kinome, a conserved member that can be traced back to early eukaryotic ancestors, similar to other kinases involved in Toll‑like receptor (TLR) signaling (gosu2012molecularevolutionand pages 1-2). Moreover, analyses using sequence alignments and functional divergence methodologies indicate that IRAK4 emerged as the primordial active kinase among its paralogs with subsequent gene duplication events giving rise to additional members like IRAK1, IRAK2, and the catalytically inactive IRAKM. Phylogenetic studies further support that the kinase domain and death domain of IRAK4 are subject to strong purifying selection, underscoring the evolutionary pressure to maintain its catalytic and scaffolding functions in innate immunity (gosu2012molecularevolutionand pages 4-5, dossang2016thenterminalloop pages 1-2). Its group assignment places it within the IRAK family, whose roles are central to TLR and interleukin‑1 receptor (IL‑1R) signaling cascades as originally defined by large‑scale kinase cataloging efforts (Manning et al., 2002, not cited explicitly but supported by comparative analyses).

2. Reaction Catalyzed  
IRAK4 catalyzes the transfer of the γ‑phosphate group from ATP to serine or threonine residues on substrate proteins. The reaction can be described as follows: ATP + [protein]‑(L‑serine or L‑threonine) → ADP + [protein]‑phospho‑(L‑serine/threonine) + H⁺. In the context of innate immune signaling, IRAK4 phosphorylates key substrates such as IRAK1 and members of the Pellino family, initiating downstream signaling events that culminate in the activation of NF‑κB and MAP kinase cascades (hekmatnejad2010steadystatekineticcharacterization pages 1-2, wang2009irak4inhibitorsfor pages 1-2). This phosphorylation event is the critical biochemical activity that underlies IRAK4’s function as a serine/threonine kinase, thereby enabling the cascade of phosphorylation reactions that propagate the immune response.

3. Cofactor Requirements  
The catalytic activity of IRAK4 depends on the presence of divalent metal ions, most notably Mg²⁺. Mg²⁺ functions as a cofactor by forming complexes with ATP, thereby facilitating the proper positioning of the nucleotide within the active site of the kinase. This requirement is typical among kinases, and biochemical studies with IRAK4 have demonstrated the necessity of Mg²⁺ for optimal kinase activity. The dependency on Mg²⁺--as demonstrated by kinetic assays--confirms that the enzymatic function follows the classical mechanism of phosphoryl transfer observed in serine/threonine kinases (hekmatnejad2010steadystatekineticcharacterization pages 1-2).

4. Substrate Specificity  
IRAK4 exhibits substrate specificity that is central to its function in innate immune signaling. One of its primary substrates is IRAK1, for which IRAK4 phosphorylates specific threonine residues—most notably at residues corresponding to the activation loop (for example, T209 as reported in several studies) (li2023anoncanonicalirak4irak1 pages 1-3). In addition, IRAK4 phosphorylates E3 ubiquitin ligases such as Pellino proteins (including PELI1, PELI2, and PELI3), which, following phosphorylation, mediate polyubiquitination of IRAK1, strengthening the signal for downstream recruitment of other signaling components like IKBKG/NEMO (behairy2023unravelingextremelydamaging pages 19-21). Although precise consensus recognition motifs in terms of amino acid sequences have not been detailed as extensively in the currently available texts, the substrate recognition by IRAK4 is consistent with that of other serine/threonine kinases, with its active site structured to accommodate polar and charged residues that flank the phosphorylated serine or threonine (wang2009irak4inhibitorsfor pages 13-14). Thus, the kinase preferably targets substrates that contain appropriate residues required for formation of stable interactions within the catalytic cleft.

5. Structure  
IRAK4 is organized into distinct domains that contribute to both its signaling and catalytic roles. At the N‑terminus, it contains a death domain (DD), which mediates homotypic interactions with adaptor proteins such as MyD88 and facilitates formation of the Myddosome—a multiprotein signaling complex essential for TLR and IL‑1R signaling (behairy2023unravelingextremelydamaging pages 26-28, dossang2016thenterminalloop pages 1-2). Immediately following this is a less well‐defined Pro‑Ser‑Thr (PST) rich region that is thought to contribute to flexible linker functions. The primary catalytic unit of IRAK4 is the C‑terminal kinase domain, a bilobal structure with a smaller N‑lobe dominated by β‑sheet architecture and a larger C‑lobe that is predominantly α‑helical. Within this kinase domain are highly conserved motifs, including a glycine‑rich “G‑loop” that binds ATP, a catalytic loop that contains the active site aspartate, and an activation segment (or activation loop) that includes regulatory phosphorylation sites such as Thr345 and Ser346 (behairy2023unravelingextremelydamaging pages 19-21, wang2009irak4inhibitorsfor pages 12-13). A unique structural feature of IRAK4 is its tyrosine gatekeeper residue (Tyr262), which distinguishes its ATP‑binding pocket from that of many other kinases; this bulky residue blocks access to a typically available hydrophobic pocket, thereby influencing both substrate specificity and the design of selective inhibitors (wang2009irak4inhibitorsfor pages 6-8, wang2019conformationalflexibilityand pages 5-7). Additionally, the kinase domain includes a “regulatory spine” composed of hydrophobic residues that is critical for the proper alignment of catalytic elements and is rearranged upon activation through phosphorylation (wang2019conformationalflexibilityand pages 3-4). These structural elements together create an enzyme that is capable of transitioning between inactive “open” conformations and an active “closed” conformation upon autophosphorylation, a critical step that modulates its catalytic activity (behairy2023unravelingextremelydamaging pages 4-6, koziczakholbro2007irak4kinaseactivity pages 1-2).

6. Regulation  
IRAK4 regulation occurs through multiple interconnected mechanisms. A key aspect of its regulation involves autophosphorylation; upon recruitment to receptor complexes via interactions with MyD88, IRAK4 dimerizes and undergoes trans‑autophosphorylation at critical residues located in its activation loop—particularly Thr345 and Ser346—which serve to relieve autoinhibition and generate an active kinase conformation (behairy2023unravelingextremelydamaging pages 19-21, wang2019conformationalflexibilityand pages 16-18). The death domain of IRAK4 also plays a regulatory role by mediating protein–protein interactions. This domain facilitates the assembly of the Myddosome, which is required for effective downstream signaling (dossang2016thenterminalloop pages 6-8). In addition, regulation of IRAK4 extends to its influence on other proteins; for example, IRAK4 phosphorylates Pellino family E3 ubiquitin ligases, which in turn catalyze the polyubiquitination of IRAK1. Such ubiquitination events are critical for the recruitment of downstream adaptor and effector proteins culminating in NF‑κB activation (behairy2023unravelingextremelydamaging pages 26-28). Although the detailed kinetics of substrate interaction have been explored, IRAK4 regulation is also modulated by its ability to cycle between inactive and active conformations, a process influenced by both autophosphorylation and binding of ATP or specific inhibitors (hekmatnejad2010steadystatekineticcharacterization pages 11-11, wang2009irak4inhibitorsfor pages 3-4). Each of these layers of regulation functions in a coordinated manner to ensure that IRAK4 activation is appropriately triggered in response to pathogen‑associated signals and is kept in check to prevent aberrant inflammation.

7. Function  
IRAK4 plays a central role as an initiator of innate immune responses. Upon engagement of Toll‑like receptors (TLRs) or the interleukin‑1 receptor (IL‑1R), MyD88 rapidly recruits IRAK4 to the receptor complex through death domain interactions, resulting in Myddosome assembly. Within this signaling complex, IRAK4 phosphorylates IRAK1, which subsequently undergoes autophosphorylation. The cascade that follows involves the recruitment of additional signaling components, for example the E3 ubiquitin ligases Pellino proteins. The phosphorylation of these ligases by IRAK4 leads to the polyubiquitination of IRAK1, enabling its association with the IKBKG/NEMO–IKK complex and eventually culminating in the activation of NF‑κB and MAP kinase pathways (behairy2023unravelingextremelydamaging pages 19-21, li2023anoncanonicalirak4irak1 pages 1-3). The net result of these phosphorylation events is the transcriptional upregulation of various pro‑inflammatory cytokines, chemokines, and other mediators involved in host defense against pathogens. Furthermore, IRAK4 has been implicated in non‑canonical signaling pathways; recent evidence indicates that following DNA damage induced by ionizing radiation, IRAK4 can be activated via an ATR‑dependent mechanism independent of MyD88, leading to the phosphorylation and nuclear translocation of IRAK1 where it interferes with pro‑apoptotic complexes (li2023anoncanonicalirak4irak1 pages 9-11, li2023anoncanonicalirak pages 5-8). This dual functionality in both conventional TLR/IL‑1R signaling pathways and non‑canonical DNA damage response pathways highlights IRAK4’s role as a multipurpose regulator of cell survival and immune responses. In immune‑competent cells, IRAK4 is predominantly expressed in tissues with high innate immune activity and functions as a key mediator in initiating cytokine production in response to microbial challenges (wang2009irak4inhibitorsfor pages 2-3, dossang2016thenterminalloop pages 1-2).

8. Other Comments  
IRAK4 has emerged as a critical target for therapeutic intervention in inflammatory and autoimmune diseases as well as in conditions where aberrant innate immune signaling contributes to pathology. Several small‑molecule inhibitors targeting the ATP‑binding pocket of IRAK4 have been developed and are currently under investigation in preclinical studies. These inhibitors, such as HG‑12‑6 and other type I and type II inhibitors, exploit unique structural features of the IRAK4 kinase domain—including the bulky Tyr262 gatekeeper and distinct conformations of the activation loop—to achieve selectivity (wang2009irak4inhibitorsfor pages 4-6, wang2019conformationalflexibilityand pages 5-7). Disease‑associated variants of IRAK4 have been identified through in silico analyses to be potentially deleterious, compromising protein stability and autophosphorylation, which in turn affects downstream signaling efficiency (behairy2023unravelingextremelydamaging pages 23-25). Deficiencies in IRAK4 activity are causative for immunodeficiencies, characterized by recurrent pyogenic bacterial infections in childhood, while hyperactivation may contribute to chronic inflammatory disorders. In addition, recent studies have extended the functional profile of IRAK4 to include a role in the regulation of cell survival following genotoxic stress, thereby implicating it in the resistance of tumor cells to radiotherapy (li2023anoncanonicalirak4irak1 pages 9-11). These observations have spurred interest in the potential for IRAK4 inhibitors to be used either alone or in combination with other therapies to modulate inflammatory responses or to overcome therapy resistance in cancers. Thus, IRAK4 remains a protein of considerable translatable interest in the context of personalized medicine.

9. References  
1. behairy2023unravelingextremelydamaging pages 19-21  
2. behairy2023unravelingextremelydamaging pages 26-28  
3. dossang2016thenterminalloop pages 1-2  
4. dossang2016thenterminalloop pages 6-8  
5. hekmatnejad2010steadystatekineticcharacterization pages 1-2  
6. hekmatnejad2010steadystatekineticcharacterization pages 11-11  
7. li2023anoncanonicalirak4irak1 pages 1-3  
8. li2023anoncanonicalirak4irak1 pages 9-11  
9. wang2009irak4inhibitorsfor pages 1-2  
10. wang2009irak4inhibitorsfor pages 12-12  
11. wang2009irak4inhibitorsfor pages 12-13  
12. wang2009irak4inhibitorsfor pages 13-14  
13. wang2009irak4inhibitorsfor pages 2-3  
14. wang2009irak4inhibitorsfor pages 3-4  
15. wang2009irak4inhibitorsfor pages 6-8  
16. wang2019conformationalflexibilityand pages 1-2  
17. wang2019conformationalflexibilityand pages 3-4  
18. wang2019conformationalflexibilityand pages 5-7  
19. wang2019conformationalflexibilityand pages 16-18  
20. gosu2012molecularevolutionand pages 1-2  
21. gosu2012molecularevolutionand pages 4-5  
22. dardick2012nonarginineaspartate(nonrd)kinases pages 6-7  
23. koziczakholbro2007irak4kinaseactivity pages 1-1  
24. koziczakholbro2007irak4kinaseactivity pages 1-2  

(Note: Additional references and citation details are derived from the provided context and valid citation keys.)

References

1. (behairy2023unravelingextremelydamaging pages 19-21): Mohammed Y. Behairy, Refaat A. Eid, Hassan M. Otifi, Heitham M. Mohammed, Mohammed A. Alshehri, Ashwag Asiri, Majed Aldehri, Mohamed Samir A. Zaki, Khaled M. Darwish, Sameh S. Elhady, Nahla H. El-Shaer, and Muhammad Alaa Eldeen. Unraveling extremely damaging irak4 variants and their potential implications for irak4 inhibitor efficacy. Journal of Personalized Medicine, 13:1648, Nov 2023. URL: https://doi.org/10.3390/jpm13121648, doi:10.3390/jpm13121648. This article has 2 citations and is from a peer-reviewed journal.

2. (behairy2023unravelingextremelydamaging pages 26-28): Mohammed Y. Behairy, Refaat A. Eid, Hassan M. Otifi, Heitham M. Mohammed, Mohammed A. Alshehri, Ashwag Asiri, Majed Aldehri, Mohamed Samir A. Zaki, Khaled M. Darwish, Sameh S. Elhady, Nahla H. El-Shaer, and Muhammad Alaa Eldeen. Unraveling extremely damaging irak4 variants and their potential implications for irak4 inhibitor efficacy. Journal of Personalized Medicine, 13:1648, Nov 2023. URL: https://doi.org/10.3390/jpm13121648, doi:10.3390/jpm13121648. This article has 2 citations and is from a peer-reviewed journal.

3. (hekmatnejad2010steadystatekineticcharacterization pages 1-2): Mohammad Hekmat-Nejad, Terrence Cai, and David C. Swinney. Steady-state kinetic characterization of kinase activity and requirements for mg2+ of interleukin-1 receptor-associated kinase-4. Biochemistry, 49 7:1495-506, Feb 2010. URL: https://doi.org/10.1021/bi901609m, doi:10.1021/bi901609m. This article has 8 citations and is from a peer-reviewed journal.

4. (hekmatnejad2010steadystatekineticcharacterization pages 11-11): Mohammad Hekmat-Nejad, Terrence Cai, and David C. Swinney. Steady-state kinetic characterization of kinase activity and requirements for mg2+ of interleukin-1 receptor-associated kinase-4. Biochemistry, 49 7:1495-506, Feb 2010. URL: https://doi.org/10.1021/bi901609m, doi:10.1021/bi901609m. This article has 8 citations and is from a peer-reviewed journal.

5. (wang2009irak4inhibitorsfor pages 1-2): Zhulun Wang, Holger Wesche, Tracey Stevens, Nigel Walker, and Wen-Chen Yeh. Irak-4 inhibitors for inflammation. Current Topics in Medicinal Chemistry, 9:724-737, May 2009. URL: https://doi.org/10.2174/156802609789044407, doi:10.2174/156802609789044407. This article has 183 citations and is from a peer-reviewed journal.

6. (wang2009irak4inhibitorsfor pages 12-12): Zhulun Wang, Holger Wesche, Tracey Stevens, Nigel Walker, and Wen-Chen Yeh. Irak-4 inhibitors for inflammation. Current Topics in Medicinal Chemistry, 9:724-737, May 2009. URL: https://doi.org/10.2174/156802609789044407, doi:10.2174/156802609789044407. This article has 183 citations and is from a peer-reviewed journal.

7. (wang2009irak4inhibitorsfor pages 12-13): Zhulun Wang, Holger Wesche, Tracey Stevens, Nigel Walker, and Wen-Chen Yeh. Irak-4 inhibitors for inflammation. Current Topics in Medicinal Chemistry, 9:724-737, May 2009. URL: https://doi.org/10.2174/156802609789044407, doi:10.2174/156802609789044407. This article has 183 citations and is from a peer-reviewed journal.

8. (wang2009irak4inhibitorsfor pages 13-14): Zhulun Wang, Holger Wesche, Tracey Stevens, Nigel Walker, and Wen-Chen Yeh. Irak-4 inhibitors for inflammation. Current Topics in Medicinal Chemistry, 9:724-737, May 2009. URL: https://doi.org/10.2174/156802609789044407, doi:10.2174/156802609789044407. This article has 183 citations and is from a peer-reviewed journal.

9. (wang2009irak4inhibitorsfor pages 2-3): Zhulun Wang, Holger Wesche, Tracey Stevens, Nigel Walker, and Wen-Chen Yeh. Irak-4 inhibitors for inflammation. Current Topics in Medicinal Chemistry, 9:724-737, May 2009. URL: https://doi.org/10.2174/156802609789044407, doi:10.2174/156802609789044407. This article has 183 citations and is from a peer-reviewed journal.

10. (wang2009irak4inhibitorsfor pages 3-4): Zhulun Wang, Holger Wesche, Tracey Stevens, Nigel Walker, and Wen-Chen Yeh. Irak-4 inhibitors for inflammation. Current Topics in Medicinal Chemistry, 9:724-737, May 2009. URL: https://doi.org/10.2174/156802609789044407, doi:10.2174/156802609789044407. This article has 183 citations and is from a peer-reviewed journal.

11. (wang2009irak4inhibitorsfor pages 6-8): Zhulun Wang, Holger Wesche, Tracey Stevens, Nigel Walker, and Wen-Chen Yeh. Irak-4 inhibitors for inflammation. Current Topics in Medicinal Chemistry, 9:724-737, May 2009. URL: https://doi.org/10.2174/156802609789044407, doi:10.2174/156802609789044407. This article has 183 citations and is from a peer-reviewed journal.

12. (behairy2023unravelingextremelydamaging pages 4-6): Mohammed Y. Behairy, Refaat A. Eid, Hassan M. Otifi, Heitham M. Mohammed, Mohammed A. Alshehri, Ashwag Asiri, Majed Aldehri, Mohamed Samir A. Zaki, Khaled M. Darwish, Sameh S. Elhady, Nahla H. El-Shaer, and Muhammad Alaa Eldeen. Unraveling extremely damaging irak4 variants and their potential implications for irak4 inhibitor efficacy. Journal of Personalized Medicine, 13:1648, Nov 2023. URL: https://doi.org/10.3390/jpm13121648, doi:10.3390/jpm13121648. This article has 2 citations and is from a peer-reviewed journal.

13. (dardick2012nonarginineaspartate(nonrd)kinases pages 6-7): Chris Dardick, Benjamin Schwessinger, and Pamela Ronald. Non-arginine-aspartate (non-rd) kinases are associated with innate immune receptors that recognize conserved microbial signatures. Current Opinion in Plant Biology, 15:358-366, Aug 2012. URL: https://doi.org/10.1016/j.pbi.2012.05.002, doi:10.1016/j.pbi.2012.05.002. This article has 142 citations and is from a peer-reviewed journal.

14. (dossang2016thenterminalloop pages 1-2): Anthony C. G. Dossang, Precious G. Motshwene, Yang Yang, Martyn F. Symmons, Clare E. Bryant, Satty Borman, Julie George, Alexander N. R. Weber, and Nicholas J. Gay. The n-terminal loop of irak-4 death domain regulates ordered assembly of the myddosome signalling scaffold. Scientific Reports, Nov 2016. URL: https://doi.org/10.1038/srep37267, doi:10.1038/srep37267. This article has 27 citations and is from a poor quality or predatory journal.

15. (dossang2016thenterminalloop pages 6-8): Anthony C. G. Dossang, Precious G. Motshwene, Yang Yang, Martyn F. Symmons, Clare E. Bryant, Satty Borman, Julie George, Alexander N. R. Weber, and Nicholas J. Gay. The n-terminal loop of irak-4 death domain regulates ordered assembly of the myddosome signalling scaffold. Scientific Reports, Nov 2016. URL: https://doi.org/10.1038/srep37267, doi:10.1038/srep37267. This article has 27 citations and is from a poor quality or predatory journal.

16. (gosu2012molecularevolutionand pages 1-2): Vijayakumar Gosu, Shaherin Basith, Prasannavenkatesh Durai, and Sangdun Choi. Molecular evolution and structural features of irak family members. PLoS ONE, 7:e49771, Nov 2012. URL: https://doi.org/10.1371/journal.pone.0049771, doi:10.1371/journal.pone.0049771. This article has 64 citations and is from a peer-reviewed journal.

17. (gosu2012molecularevolutionand pages 4-5): Vijayakumar Gosu, Shaherin Basith, Prasannavenkatesh Durai, and Sangdun Choi. Molecular evolution and structural features of irak family members. PLoS ONE, 7:e49771, Nov 2012. URL: https://doi.org/10.1371/journal.pone.0049771, doi:10.1371/journal.pone.0049771. This article has 64 citations and is from a peer-reviewed journal.

18. (koziczakholbro2007irak4kinaseactivity pages 1-1): Magdalena Koziczak-Holbro, Claire Joyce, Anton Glück, Bernd Kinzel, Matthias Müller, Claude Tschopp, John C. Mathison, Christopher N. Davis, and Hermann Gram. Irak-4 kinase activity is required for interleukin-1 (il-1) receptor- and toll-like receptor 7-mediated signaling and gene expression*. Journal of Biological Chemistry, 282:13552-13560, May 2007. URL: https://doi.org/10.1074/jbc.m700548200, doi:10.1074/jbc.m700548200. This article has 110 citations and is from a domain leading peer-reviewed journal.

19. (koziczakholbro2007irak4kinaseactivity pages 1-2): Magdalena Koziczak-Holbro, Claire Joyce, Anton Glück, Bernd Kinzel, Matthias Müller, Claude Tschopp, John C. Mathison, Christopher N. Davis, and Hermann Gram. Irak-4 kinase activity is required for interleukin-1 (il-1) receptor- and toll-like receptor 7-mediated signaling and gene expression*. Journal of Biological Chemistry, 282:13552-13560, May 2007. URL: https://doi.org/10.1074/jbc.m700548200, doi:10.1074/jbc.m700548200. This article has 110 citations and is from a domain leading peer-reviewed journal.

20. (li2023anoncanonicalirak pages 5-8): Yuanyuan Li, Richa B. Shah, Samanta Sarti, Alicia L. Belcher, Brian J. Lee, Andrej Gorbatenko, Francesca Nemati, Ian Yu, Zoe Stanley, Zhengping Shao, Jose M. Silva, Shan Zha, and Samuel Sidi. A non-canonical irak signaling pathway triggered by dna damage. BioRxiv, Feb 2023. URL: https://doi.org/10.1101/2023.02.08.527716, doi:10.1101/2023.02.08.527716. This article has 2 citations.

21. (li2023anoncanonicalirak4irak1 pages 1-3): Yuanyuan Li, Richa B. Shah, Samanta Sarti, Alicia L. Belcher, Brian J. Lee, Andrej Gorbatenko, Francesca Nemati, Honglin Yu, Zoe Stanley, Mahbuba Rahman, Zhengping Shao, Jose M. Silva, Shan Zha, and Samuel Sidi. A noncanonical irak4-irak1 pathway counters dna damage–induced apoptosis independently of tlr/il-1r signaling. Science Signaling, Dec 2023. URL: https://doi.org/10.1126/scisignal.adh3449, doi:10.1126/scisignal.adh3449. This article has 5 citations and is from a domain leading peer-reviewed journal.

22. (li2023anoncanonicalirak4irak1 pages 9-11): Yuanyuan Li, Richa B. Shah, Samanta Sarti, Alicia L. Belcher, Brian J. Lee, Andrej Gorbatenko, Francesca Nemati, Honglin Yu, Zoe Stanley, Mahbuba Rahman, Zhengping Shao, Jose M. Silva, Shan Zha, and Samuel Sidi. A noncanonical irak4-irak1 pathway counters dna damage–induced apoptosis independently of tlr/il-1r signaling. Science Signaling, Dec 2023. URL: https://doi.org/10.1126/scisignal.adh3449, doi:10.1126/scisignal.adh3449. This article has 5 citations and is from a domain leading peer-reviewed journal.

23. (wang2009irak4inhibitorsfor pages 4-6): Zhulun Wang, Holger Wesche, Tracey Stevens, Nigel Walker, and Wen-Chen Yeh. Irak-4 inhibitors for inflammation. Current Topics in Medicinal Chemistry, 9:724-737, May 2009. URL: https://doi.org/10.2174/156802609789044407, doi:10.2174/156802609789044407. This article has 183 citations and is from a peer-reviewed journal.

24. (wang2019conformationalflexibilityand pages 1-2): Li Wang, Ryan Ferrao, Qiubai Li, John M. Hatcher, Hwan Geun Choi, Sara J. Buhrlage, Nathanael S. Gray, and Hao Wu. Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor–associated kinase 4 (irak4). Journal of Biological Chemistry, 294:4511-4519, Mar 2019. URL: https://doi.org/10.1074/jbc.ra118.005428, doi:10.1074/jbc.ra118.005428. This article has 18 citations and is from a domain leading peer-reviewed journal.

25. (wang2019conformationalflexibilityand pages 16-18): Li Wang, Ryan Ferrao, Qiubai Li, John M. Hatcher, Hwan Geun Choi, Sara J. Buhrlage, Nathanael S. Gray, and Hao Wu. Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor–associated kinase 4 (irak4). Journal of Biological Chemistry, 294:4511-4519, Mar 2019. URL: https://doi.org/10.1074/jbc.ra118.005428, doi:10.1074/jbc.ra118.005428. This article has 18 citations and is from a domain leading peer-reviewed journal.

26. (wang2019conformationalflexibilityand pages 3-4): Li Wang, Ryan Ferrao, Qiubai Li, John M. Hatcher, Hwan Geun Choi, Sara J. Buhrlage, Nathanael S. Gray, and Hao Wu. Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor–associated kinase 4 (irak4). Journal of Biological Chemistry, 294:4511-4519, Mar 2019. URL: https://doi.org/10.1074/jbc.ra118.005428, doi:10.1074/jbc.ra118.005428. This article has 18 citations and is from a domain leading peer-reviewed journal.

27. (wang2019conformationalflexibilityand pages 5-7): Li Wang, Ryan Ferrao, Qiubai Li, John M. Hatcher, Hwan Geun Choi, Sara J. Buhrlage, Nathanael S. Gray, and Hao Wu. Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor–associated kinase 4 (irak4). Journal of Biological Chemistry, 294:4511-4519, Mar 2019. URL: https://doi.org/10.1074/jbc.ra118.005428, doi:10.1074/jbc.ra118.005428. This article has 18 citations and is from a domain leading peer-reviewed journal.

28. (behairy2023unravelingextremelydamaging pages 23-25): Mohammed Y. Behairy, Refaat A. Eid, Hassan M. Otifi, Heitham M. Mohammed, Mohammed A. Alshehri, Ashwag Asiri, Majed Aldehri, Mohamed Samir A. Zaki, Khaled M. Darwish, Sameh S. Elhady, Nahla H. El-Shaer, and Muhammad Alaa Eldeen. Unraveling extremely damaging irak4 variants and their potential implications for irak4 inhibitor efficacy. Journal of Personalized Medicine, 13:1648, Nov 2023. URL: https://doi.org/10.3390/jpm13121648, doi:10.3390/jpm13121648. This article has 2 citations and is from a peer-reviewed journal.